QIAGEN N.V. (QGEN) recently announced a sequence of new products to augment cancer research further and to enable urine collection and stabilization as a new approach for liquid biopsy. The three new products, coupled with the IVD version of QIAGEN's digital PCR platform QIAcuity, are planned to be released in mid-2024.The new products are likely to be featured at the annual meeting of the American Association for Cancer Research (AACR) in San Diego, California, from Apr 5-10.Product DetailsThe first produc ...